Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Vomiting: early-phase trial registry

7 of 10 indexed Vomiting trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Vomiting: 10 US clinical trials tracked, 7 recruiting.

Vomiting is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Enterra Medical, running 1 of these trials.

Enrollment posture brief

Registry condition vomiting

OPEN 7 | RECR 70% | LATE 1 | EARLY 5 | RANK #1724 | SPON 1

Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)

Acute Leukemia of Ambiguous 80%Vomiting (this)70%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Vomiting

Vomiting lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vomiting on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vomiting is recruiting above its size-band peers.

    7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Vomiting trials is spread across many organizations.

    Enterra Medical accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Vomiting trials plan to enrol fewer than 100 people.

    Median target enrolment is 84 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.

  4. Vomiting research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 41

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2 250 participants

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Montefiore Medical Center

NCT06382012

RECRUITING Phase 2 204 participants

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Eli Lilly and Company

NCT07169851

RECRUITING NA 148 participants

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

Enterra Medical

NCT06464926

RECRUITING NA 100 participants

Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

Christopher C. Thompson, MD, MSc

NCT06543316

RECRUITING Phase 2 84 participants

Inhaled Isopropyl Alcohol for Treatment of Nausea

State University of New York at Buffalo

NCT05418244

RECRUITING NA 30 participants

GI Alpha-Gal Study

University of North Carolina, Chapel Hill

NCT06268717

RECRUITING 25 participants

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

Denver Health and Hospital Authority

NCT06532734

COMPLETED Phase 2 53 participants

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

M.D. Anderson Cancer Center

NCT03040726

COMPLETED Phase 4 40 participants

Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens

University of Pittsburgh

NCT00177333

COMPLETED Phase 1 24 participants

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

GlaxoSmithKline

NCT00359177

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 4 1

Named interventions

Most-linked intervention names on Vomiting records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

GW679769 Drug
1 trials
Netupitant Drug
1 trials
Palonosetron Hydrochloride Drug
1 trials
Palonosetron Drug
1 trials
Standard of Care Ulcer Treatment (typically PPI Administration) Other
1 trials
Low Thermal Plasma (LTP) Treatment Procedure
1 trials
EsoGuard Device
1 trials
Enterra Therapy System Device
1 trials

US sites by state

Facility locations filed on Vomiting trials. A trial with sites in several states counts in each.

Texas 3 trials
New York 3 trials
Florida 3 trials
Pennsylvania 2 trials
North Carolina 2 trials
Illinois 2 trials
Colorado 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vomiting page

10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vomiting condition card totals 10 registered trials; most-linked intervention GW679769; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.